Session » (1306–1346) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II

Date: Monday, October 27, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 1331

Anti-beta-2-glycoprotein-1 IgA antibodies facilitate macrophage cholesterol loading and influence coronary atherosclerosis progression in a dose-dependent manner in rheumatoid arthritis

10:30AM-12:30PM: Abstract Number: 1333

Assessment of lipid abnormalities after initiation of a JAK inhibitor in rheumatoid arthritis in clinical practice

10:30AM-12:30PM: Abstract Number: 1326

Association Between Physical Function and Nutritional Status in Rheumatoid Arthritis Patients

10:30AM-12:30PM: Abstract Number: 1334

Cardiac Biomarkers and Prediction of Major Cardiovascular Events in Rheumatoid Arthritis: Results from the ESPOIR Cohort

10:30AM-12:30PM: Abstract Number: 1335

Chest x-Ray and pulmonary function tests are not sensitive for screening intertitial lung disease in reumatoid arthritis

10:30AM-12:30PM: Abstract Number: 1311

Decade-Based Trends in First Remission Among Rheumatoid Arthritis Patients: A Population-Based Study

10:30AM-12:30PM: Abstract Number: 1318

Diagnostic Delay in Rheumatoid Arthritis and its Impact on Radiographic Outcomes: A Systematic Review and Meta-analysis of 100,066 Patients

10:30AM-12:30PM: Abstract Number: 1340

Does Moderate Alcohol Use Lower Disease Activity Among Patients with Rheumatoid Arthritis?

10:30AM-12:30PM: Abstract Number: 1336

Effectiveness of new initiators of tofacitinib and other biologic/targeted synthetic DMARDs in patients with rheumatoid arthritis

10:30AM-12:30PM: Abstract Number: 1321

Efficacy and safety of janus kinase inhibitors in diffuse interstitial lung disease in rheumatoid arthritis. Systematic review

10:30AM-12:30PM: Abstract Number: 1323

Efficacy of Olokizumab in Treating Comorbid Depression in Patients with Rheumatoid Arthritis: Results of a Single-Center Randomized Controlled Trial

10:30AM-12:30PM: Abstract Number: 1312

Evolution of patients with active rheumatoid arthritis: analysis of disease activity trajectories in a tertiary‑care rheumatology department

10:30AM-12:30PM: Abstract Number: 1344

Exploring the Factors Associated with the Discontinuation of Tofacitinib in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study

10:30AM-12:30PM: Abstract Number: 1322

High Rheumatoid Factor Titers and Biologic Persistence in RA: Beyond TNF Inhibitors

10:30AM-12:30PM: Abstract Number: 1315

High-resolution thermography and Artificial Intelligence to evaluate and classify Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1339

Inflammatory Rheumatic Diseases in IDH-mutated Myeloid Neoplasms: Clinical Spectrum and Response to IDH Inhibitors

10:30AM-12:30PM: Abstract Number: 1332

Mid‐Infrared Spectroscopy for Enhanced Diagnosis of Rheumatic Diseases

10:30AM-12:30PM: Abstract Number: 1328

Mortality Trends of Hypertension in Patients with Rheumatoid Arthritis in the United States (1999–2020)

10:30AM-12:30PM: Abstract Number: 1310

Naturalized Language Processing Based Extraction of Rheumatoid Arthritis Disease Activity Measures from the Electronic Health Record

10:30AM-12:30PM: Abstract Number: 1341

Physical Function Across Age in Patients With Rheumatoid Arthritis and Population Controls: A Cross-Sectional Study of Four Performance Measures

10:30AM-12:30PM: Abstract Number: 1307

Plasma levels of monounsaturated fatty acids (MUFAs) positively correlate with disease activity in patients with rheumatoid arthritis (RA)

10:30AM-12:30PM: Abstract Number: 1325

Plasma Matrix Metalloproteinases and Heart Failure Outcomes in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1316

Predicting mortality of rheumatoid arthritis in China: A nation-wide cohort study

10:30AM-12:30PM: Abstract Number: 1308

Predictors of Interstitial Lung Disease Progression in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1346

Preliminary Result of Investigating the Response of Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) Associated SNPs: One Cohort Study

10:30AM-12:30PM: Abstract Number: 1314

Protein-Specific Anti-Malondialdehyde-Acetaldehyde Antibodies and Cardiovascular Disease Outcomes in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1329

Relationship Between Circulating Bacterial Small RNAs, Methotrexate Response, and Microbiome in New Onset Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1313

Retrospective Analysis of Factors Associated With Fracture in 2855 Patients With Rheumatoid Arthritis, Stratified by Steroid Use

10:30AM-12:30PM: Abstract Number: 1330

Sex and reproductive stage modify the role of endogenous estrogens on coronary atherosclerosis in rheumatoid arthritis and differences reflect effects on inflammation and cholesterol metabolism

10:30AM-12:30PM: Abstract Number: 1338

Short-Chain Fatty Acids and Their Gut Microbial Metabolic Pathways Distinguish Rheumatoid Arthritis in Discordant Monozygotic Twins

10:30AM-12:30PM: Abstract Number: 1324

Similar Negative Effects of Fatigue on Physical Activity in Persons with Rheumatoid Arthritis and Healthy Controls: A Patient-Control Study

10:30AM-12:30PM: Abstract Number: 1343

Six-Minute Walk Distance as a Functional Measure in Rheumatoid Arthritis-associated Interstitial Lung Disease Reflecting Both Lung and Joint Involvement

10:30AM-12:30PM: Abstract Number: 1306

Systematic Literature Review of Digital Sleep Outcomes and Endpoints Used to Assess Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1327

Systematic Review of Mobility in Rheumatoid Arthritis with Digitally Measured Objective Assessment

10:30AM-12:30PM: Abstract Number: 1337

The Association Between Glucagon-Like Peptide-1 Receptor Agonist and Rheumatoid Arthritis: A Population-Based Case Control Study

10:30AM-12:30PM: Abstract Number: 1317

The Association Between Insomnia and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 546,822 Patients

10:30AM-12:30PM: Abstract Number: 1319

The Association of Rheumatoid Arthritis in Patients with Vitiligo: Systematic Review and Meta-Analysis

10:30AM-12:30PM: Abstract Number: 1342

The Impact of Age on Health-Related Quality of Life in Patients With Rheumatoid Arthritis Compared to Population Controls: A Cross-Sectional Analysis

10:30AM-12:30PM: Abstract Number: 1309

Transcriptomic biomarkers of progression from undifferentiated arthritis to rheumatoid arthritis

10:30AM-12:30PM: Abstract Number: 1320

Trends In Incidence and Risk factors For Incident Venous Thromboembolism in Patients with Rheumatoid Arthritis: A Population-Based Retrospective Cohort Study

10:30AM-12:30PM: Abstract Number: 1345

Upregulated TLR Signaling Identified in Difficult-to-Treat RA: A Propensity Score–Matched Transcriptome Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].